Vanda Q1 2023 revenue $62.5M (+4% YoY); net income $3.3M vs loss

Vanda Pharmaceuticals Inc.

2023-Q1 EPS reported $0.06 revenue$62,498,000

Net product sales: HETLIOZ $39.6M (+7% YoY), Fanapt $22.9M (-1% YoY).
Diluted EPS $0.06 vs ($0.11) in prior year; cash $501.5M (+15% YoY).
Expects sNDA for Fanapt in bipolar I disorder and NDA for tradipitant in gastroparesis in Q2 2023.
At-risk generic HETLIOZ launch in U.S. likely to cause significant future sales decline; no 2023 guidance provided.
Awaiting Federal Circuit ruling on HETLIOZ patent appeal; won FOIA lawsuit against FDA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vanda Pharmaceuticals Inc. reported the first quarter ended March 31, 2023 results: revenue $62.5 million, net income $3.3 million, EPS diluted net income per share was $0.06.

Period: the first quarter ended March 31, 2023
Revenue: $62.5 million
Net income: $3.3 million
EPS: diluted net income per share was $0.06
Result: reported results

Exact text from the filing

set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results • Q1 2023 total revenues were $62.5 million • Vanda provides update on three upcoming regulatory submissions WASHINGTON – May 3, 2023 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and

View on SEC.gov

Browse all earnings releases →

Vanda Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-015206

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.